Early recurrence of atrial tachyarrhythmia indicates pulmonary vein reconduction independent of blanking period duration in the RACE-AF trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 1,18 MB, PDF-dokument

Introduction: Atrial tachyarrhythmia recurrence during the blanking period (early ATA) after pulmonary vein isolation (PVI) is associated with an increased risk of later recurrence, but its relationship with pulmonary vein reconduction (PVR) is poorly understood. The objective of the present study was to evaluate the relationship between early ATA and PVR. Second, to provide data on the optimal blanking period by (a) evaluating how the predictive values of ATA for PVR are affected by blanking period duration, and (b) assessing the temporal development in atrial fibrillation (AF) burden. Methods: In this RACE-AF substudy, 91 patients with paroxysmal AF undergoing PVI randomized to radiofrequency or cryoballoon ablation were included. All patients received an implantable cardiac monitor and underwent a protocol-mandated repeat procedure after 4–6 months for assessment of PVR. ATA ≥ 30 s. ≤ 90 days after PVI constituted early ATA. Results: PVR was found in 37/54 (69%) patients with early ATA and in 11/37 (30%) patients without (p <.001). The positive predictive value of ATA for PVR was independent of blanking period duration (range 0–90 days). In both patients with and without PVR, AF burden was higher in the first month after PVI, but AF burden from the second month was similar to AF burden after the conventional blanking period. Conclusion: Early ATA indicates PVR, and the positive predictive value is independent of the blanking period duration. Altogether, the results of this study support substantially shortening the blanking period after PVI for paroxysmal AF.

OriginalsprogEngelsk
TidsskriftJournal of Cardiovascular Electrophysiology
Vol/bind34
Udgave nummer12
Sider (fra-til)2434-2442
Antal sider9
ISSN1045-3873
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
: Research stipend for Samuel K. Sørensen was in part funded by financial support from Medtronic and Biosense Webster. Jim Hansen has received research grants and speaker honoraria from Medtronic and Biosense Webster and René Worck has received research grants and speaker honoraria from Biosense Webster. Other authors: No disclosures. The study was supported by institutional funds and financial support from Medtronic and Biosense Webster. The funding sources had no part in study design, the collection, analysis, or interpretation of data, the writing of the report, or the decision to submit the article for publication. Disclosures

Publisher Copyright:
© 2023 Wiley Periodicals LLC.

ID: 389363324